Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.43, $0.13 better than the analyst estimate of $0.30. Revenue for the quarter came in at $202.3 million versus the consensus estimate of $202.37 million.

GUIDANCE:

Myriad Genetics sees FY2019 EPS of $1.70-$1.75, versus the consensus of $1.72.

• Revised Full-Year Revenue Guidance to $855 to $865 Million;
• Maintained Diluted EPS Guidance of $0.40 to $0.45 and Adjusted EPS Guidance of $1.70 to $1.75

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.